CN111197087B - Thyroid cancer differential marker - Google Patents
Thyroid cancer differential marker Download PDFInfo
- Publication number
- CN111197087B CN111197087B CN202010037595.3A CN202010037595A CN111197087B CN 111197087 B CN111197087 B CN 111197087B CN 202010037595 A CN202010037595 A CN 202010037595A CN 111197087 B CN111197087 B CN 111197087B
- Authority
- CN
- China
- Prior art keywords
- methylation
- seq
- gene
- dna
- thyroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Abstract
The invention provides a composition for identifying benign and malignant thyroid nodules, which comprises a nucleic acid sequence of a LIMK1 gene, a nucleic acid sequence of a SLC17A5 gene and a nucleic acid sequence of an internal reference gene, wherein the nucleic acid sequences are respectively used for detecting a methylation region related to the benign and malignant thyroid nodules in a sample to be detected. The invention also provides application of the composition in identification of benign and malignant thyroid nodules.
Description
Technical Field
The invention belongs to the field of molecular auxiliary diagnosis, relates to a thyroid cancer identification marker, and particularly relates to a compound for detecting methylation of a LIMK1 gene and an SLC17A5 gene and application of methylation of a LIMK1 gene and an SLC17A5 gene in identification of benign and malignant thyroid nodules.
Background
Thyroid nodules (Thyroid nodules) are masses that form in Thyroid tissue following abnormal proliferation of Thyroid cells. Thyroid nodules are very common, and although most thyroid nodules are benign, a small percentage of them progress to thyroid cancer. For earlier diagnosis and treatment of thyroid cancer, while reducing unnecessary surgery, benign and malignant identification of thyroid nodules is required.
Presently, thyroid nodules are mainly evaluated by Ultrasonography (US) and Fine Needle Aspiration Biopsy (FNAB). In the diagnostic procedure of thyroid nodules, US is currently the most sensitive examination method, and can measure the size of the nodule, determine the internal structure of the nodule, and the like. US signs suggesting that thyroid nodules are malignant include: nodule height greater than width (OR ═ 10.15), lack of acoustic halo (OR ═ 7.14), microcalcifications (OR ═ 6.76), border irregularity (OR ═ 6.12), echo reduction (OR ═ 5.07), solid nodules (OR ═ 4.69), nodule internal blood flow abundance (OR ═ 3.76), and the like. The diameter is more than 1cm, and the nodules with malignant signs are examined by ultrasonic wave and FNAB is used for judging the properties of the nodules. Up to 20% of the nodules in cytological examination are indeterminate thyroid nodules (indexaminate thyroid nodules), which require detection of binding molecules. Has been on the market
Gene Expression Classifier and Thyroseq 2 products, the Positive Predictive Value (PPV) of the former is very low, only 46%; the latter PPV is also only 42% -77%. More accurate molecular diagnostic tools are therefore needed.
DNA methylation is a mechanism of epigenetics, is a common epigenetics modification of eukaryotic cell genomes, is also an important natural chemical modification mode of vertebrate DNA under the condition of not changing DNA sequences, plays an important role in aspects of cell proliferation, differentiation, development and the like, and is closely related to the occurrence and development of tumors. DNA methylation plays an important role in vivo, and its effects are transcription repression, chromatin structure regulation, X chromosome inactivation, genomic imprinting, etc., and DNA methylation abnormalities can be involved in tumor development and progression by affecting chromatin structure and the expression of oncogenes and tumor suppressor genes.
CpG dinucleotides are the most major target for DNA methylation in mammals and are distributed throughout the entire chromosome set. In a healthy human genome, CpG sites in CpG islands are usually unmethylated, whereas CpG sites outside CpG islands are usually hypermethylated, which is stably retained during cell division. When tumors occur, the methylation degree of CpG sites in non-CpG island regions of cancer suppressor genes is generally reduced, and CpG in the CpG island is in a high methylation state, so that the chromatin structure is changed and the expression of the cancer suppressor genes is reduced.
With the continued development of genetics and epigenetics over the last decade, more and more researchers are recognizing that tumor development is not completely genetically determined, and that the acquired effects of epigenetics play an important role as well. Epigenetic alterations in thyroid cancer are mainly manifested by abnormal methylation of tumor suppressor genes and thyroid-associated genes. The research on the DNA methylation of the thyroid cancer can provide a new molecular marker for people, and provide a reliable basis for early diagnosis, treatment scheme selection and prognosis evaluation.
The current DNA methylation detection methods include: bisulfite Sequencing (BS), Methylation-specific PCR (MSP), Methylation-sensitive High-resolution Melting curve (MS-HRM), and High-throughput sequencing. Compared with other detection methods, the bisulfite sequencing method is a 'gold standard' in DNA methylation detection, is relatively accurate in detection, but is relatively low in detection sensitivity, relatively complicated in operation and high in cost. The methylation sensitive high-resolution melting curve method judges whether DNA is methylated or not by observing the change of a melting curve in PCR amplification, and the analysis of the result of the method is relatively complex. The high-throughput sequencing detection method is high in cost and long in period, and is not favorable for clinical popularization. The field needs a high-specificity and high-sensitivity kit for identifying benign and malignant thyroid nodules.
Disclosure of Invention
The invention aims to provide a composition for identifying benign and malignant thyroid nodules, and the methylation condition of target sites in a LIMK1 gene and an SLC17A5 gene is detected by using the composition to realize the identification of the benign and malignant thyroid nodules.
The present invention provides a nucleic acid molecule selected from the group consisting of: (1) a fragment of the LIMK1 gene amplified from SEQ ID NOs 1 and 2 or a sequence having at least 90% identity thereto as a primer; (2) a fragment of the SLC17A5 gene amplified from SEQ ID NOs 3 and 4 or a sequence having at least 90% identity thereto as primers; and (3) a mixture of the fragments of (1) and (2).
In one or more embodiments, unmethylated cytosines in the fragment are converted to bases that do not bind guanine.
The invention also provides a primer molecule selected from: (1) 1 and 2 or a sequence having at least 90% identity thereto; (2) 3 and 4 or a sequence having at least 90% identity thereto; and (3) mixtures of the sequences described in (1) and (2).
In one or more embodiments, the primer molecules further comprise primers for detecting the reference gene ACTB, wherein the primers for detecting the reference gene ACTB amplify a segment of the ACTB gene amplified from SEQ ID NOs 5 and 6 or sequences at least 90% identical thereto as primers. Preferably, the primers for detecting the reference gene ACTB are SEQ ID NO's 5 and 6 or sequences at least 90% identical thereto.
The invention also provides a probe molecule capable of hybridising to one or more fragments selected from the group consisting of: a fragment of LIMK1 gene amplified by using SEQ ID NO. 1 and 2 as primers, a fragment of SLC17A5 gene amplified by using SEQ ID NO. 3 and 4 as primers, and optionally a fragment of ACTB gene amplified by using SEQ ID NO. 5 and 6 as primers.
Preferably, the probe molecule comprises the sequences shown in SEQ ID NO 7 and 8 or sequences at least 90% identical thereto and optionally the sequence shown in SEQ ID NO 9 or sequences at least 90% identical thereto.
The invention also provides a composition for identifying benign and malignant thyroid nodules, which comprises nucleic acid molecules for detecting the LIMK1 gene and the SLC17A5 gene which are related to the benign and malignant thyroid nodules in a sample respectively, and optionally nucleic acid molecules for detecting an internal reference gene.
In one or more embodiments, the detecting is detecting a methylation level.
Specifically, the invention provides a composition for identifying benign and malignant thyroid nodules, which comprises a nucleic acid sequence of a LIMK1 gene and a nucleic acid sequence of a SLC17A5 gene which are respectively used for detecting a methylation region related to the benign and malignant thyroid nodules in a sample to be detected, and a nucleic acid sequence of an internal reference gene.
In one or more embodiments, the nucleic acid molecule detecting the LIMK1 gene comprises a sequence as set forth in any one of SEQ ID NOs 1-2 and the nucleic acid molecule detecting the SLC17A5 gene comprises a sequence as set forth in any one of SEQ ID NOs 3-4. The specific sequence is as follows:
LIMK1 gene forward primer F:
GTTGTGTATCGAGTGGGGTAGTG(SEQ ID NO:1)，
LIMK1 gene reverse primer R:
AAAACTAAACCACCGAAAATAATAAC(SEQ ID NO:2)，
SLC17a5 gene forward primer F:
GAGGTTTTAGTGTGATTTTTTATTGT(SEQ ID NO:3)，
SLC17a5 gene reverse primer R:
AATTTAAAATAACTCAACCCGAACG(SEQ ID NO:4)。
in one or more embodiments, the reference gene is ACTB. In one or more embodiments, the nucleic acid molecule for detecting the reference gene comprises a sequence as set forth in any one of SEQ ID NOS 5-6. The specific sequence is as follows:
reference gene forward primer F:
CCCTTAAAAATTACAAAAACCACAACC(SEQ ID NO:5)，
internal reference gene reverse primer R:
AGGAGGTTTAGTAAGTTTTTTGGATTG(SEQ ID NO:6)。
in one or more embodiments, the nucleic acid molecule is a primer.
In one or more embodiments, the composition further comprises a probe for the LIMK1 gene, a probe for the SLC17a5 gene, and a probe for an internal reference gene, each of which recognizes an amplified fragment of the corresponding nucleic acid molecule. Preferably, the probe for the LIMK1 gene comprises the sequence shown in SEQ ID NO. 7, and the probe for the SLC17A5 gene comprises the sequence shown in SEQ ID NO. 8. The specific probe sequence is as follows:
LIMK1 gene probe: TTGACGTGGCGTTTTTTGTCGTTTTTG (SEQ ID NO:7)
SLC17a5 gene probe: TCGCGAGGTTTTTATTCGTTGCGTCGTTC (SEQ ID NO: 8).
In one or more embodiments, the reference gene is ACTB. In one or more embodiments, the probe for the reference gene comprises the sequence shown in SEQ ID NO 9. The specific sequence is as follows:
internal reference gene probe: ACCACCACCCAACACACAATAACAAACACA (SEQ ID NO: 9).
In one or more embodiments, each probe further comprises a detectable moiety. In one or more embodiments, the detectable species is a5 'fluorescent reporter and a 3' labeled quencher. In one or more embodiments, the fluorescent reporter gene is selected from Cy5, Texas Red, FAM, and HEX.
Preferably, the probe sequence is as follows:
LIMK1 gene probe:
FAM-TTGACGTGGCGTTTTTTGTCGTTTTTG-BHQ1
SLC17a5 gene probe:
Cy5-TCGCGAGGTTTTTATTCGTTGCGTCGTTC-BHQ2
internal reference gene probe:
HEX-ACCACCACCCAACACACAATAACAAACACA-BHQ1。
the invention also provides a methylation detection kit for identifying benign and malignant thyroid nodules, which is characterized by comprising a primer molecule and an optional probe molecule, wherein the primer molecule can amplify a fragment of the LIMK1 gene amplified by taking SEQ ID NO. 1 and 2 or a sequence at least 90% identical to the SEQ ID NO. 1 and 2 as a primer and a fragment of the SLC17A5 gene amplified by taking SEQ ID NO. 3 and 4 or a sequence at least 90% identical to the SEQ ID NO. 3 and 4 as a primer, and the probe molecule comprises sequences shown by SEQ ID NO. 7 and 8 or a sequence at least 90% identical to the sequence.
In one or more embodiments, the kit further comprises a primer for detecting the reference gene ACTB and an optional probe molecule for detecting the reference gene ACTB, wherein the primer for detecting the reference gene ACTB can amplify a fragment of the ACTB gene obtained by amplifying SEQ ID NO. 5 and 6 or a sequence at least 90% identical thereto as a primer, and the probe molecule for detecting the reference gene ACTB comprises a sequence shown in SEQ ID NO. 9 or a sequence at least 90% identical thereto.
In one or more embodiments, the kit comprises a primer molecule described herein, optionally a nucleic acid molecule described herein, and optionally a probe molecule described herein.
In one or more embodiments, the kit further comprises a transformed positive standard in which unmethylated cytosines are converted to bases that do not bind guanine. In one or more embodiments, the positive standard is fully methylated.
In one or more embodiments, the kit further comprises PCR reaction reagents. Preferably, the PCR reaction reagent comprises Taq DNA polymerase, PCR buffer (buffer), dNTPs and Mg2+。
In one or more embodiments, the kit further comprises reagents for detecting DNA methylation, the reagents being reagents used in one or more of the following methods selected from: bisulfite conversion based PCR (e.g., methylation specific PCR), DNA sequencing (e.g., bisulfite sequencing, whole genome methylation sequencing, simplified methylation sequencing), methylation sensitive restriction enzyme analysis, fluorometry, methylation sensitive high resolution melting curve, chip-based methylation profile analysis, mass spectrometry (e.g., flight mass spectrometry). Preferably, the agent is selected from one or more of: bisulfite and its derivatives, restriction enzyme sensitive or insensitive to methylation, enzyme digestion buffer, fluorescent dye, fluorescence quencher, fluorescence reporter, exonuclease, alkaline phosphatase, internal standard, and reference substance.
In one or more embodiments, the method of identification of benign and malignant thyroid nodules is: and calculating scores according to the methylation levels of the LIMK1 and the SLC17A5, and judging the result to be positive if the score is greater than 0, namely the thyroid nodule is a malignant nodule. In one or more embodiments, a score less than 0 determines a negative result, i.e., the thyroid nodule is a benign nodule.
Preferably, the score is 3.17-0.10 × LIMK1 methylation level-0.31 × SLC17a5 methylation level.
In PCR embodiments, preferably, the methylation level is 2-delta Ct sample to be detected/2- Δ Ct positive standard X 100 where Δ Ct ═ CtTarget gene–CtInternal reference gene。
The invention also provides application of the nucleic acid molecule, the primer molecule and the probe molecule in preparation of a reagent for identifying benign and malignant thyroid nodules. In one or more embodiments, the reagents are used to detect LIMK1 methylation levels and SLC17a5 methylation levels of DNA in a sample, the identifying comprising interpreting thyroid nodule benign and malignant based on the methylation levels.
In one or more embodiments, the sample is from a tissue, cell, or bodily fluid of a mammal, such as thyroid tissue or blood. The mammal is preferably a human. In one or more embodiments, the sample is a thyroid nodule biopsy, preferably a fine needle biopsy. In one or more embodiments, the sample is plasma.
In one or more embodiments, the sample is from a subject having benign or malignant nodules of the thyroid. In one or more embodiments, the sample is from a patient with goiter.
In one or more embodiments, the DNA is whole genome DNA and/or cfDNA.
In one or more embodiments, the DNA is transformed in which unmethylated cytosines are converted to bases that do not bind guanine. The conversion is carried out using an enzymatic method, preferably a deaminase treatment, or the conversion is carried out using a non-enzymatic method, preferably a treatment with bisulfite or bisulfate, more preferably a treatment with calcium bisulfite, sodium bisulfite, potassium bisulfite, ammonium bisulfite, sodium bisulfite, potassium bisulfite and ammonium bisulfite.
In one or more embodiments, the detection includes, but is not limited to: bisulfite conversion based PCR (e.g., methylation specific PCR), DNA sequencing (e.g., bisulfite sequencing, whole genome methylation sequencing, simplified methylation sequencing), methylation sensitive restriction enzyme analysis, fluorometry, methylation sensitive high resolution melting curve, chip-based methylation profile analysis, mass spectrometry (e.g., flight mass spectrometry).
In one or more embodiments, the detection is bisulfite sequencing detection.
In one or more embodiments, the detection is a fluorescent quantitative PCR detection, further comprising the use of a probe as described herein.
In one or more embodiments, the reaction solution for PCR comprises Taq DNA polymerase, PCR buffer (buffer), dNTPs, Mg2+. Preferably, the Taq DNA polymerase is a hot start Taq DNA polymerase. Preferably, Mg2+The final concentration is 1.0-10.0 mM.
In one or more embodiments, the concentration of each primer in the PCR is 200-700 nM.
In one or more embodiments, the concentration of each probe in the PCR is 100-400 nM.
In one or more embodiments, the PCR reaction conditions are, pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 15s, annealing and extension at 60 ℃ for 1min, and 45 cycles.
In one or more embodiments, the interpretation method is: a score is calculated based on the methylation levels of both genes, and a score greater than 0 gives a positive result, i.e., the thyroid nodule is a malignant nodule. In one or more embodiments, a score less than 0 is negative, i.e., the thyroid nodule is a benign nodule.
Preferably, the score is 3.17-0.10 × LIMK1 methylation level-0.31 × SLC17a5 methylation level.
In PCR embodiments, preferably, the methylation level is 2-delta Ct sample to be detected/2- Δ Ct positive standard X 100, where Δ Ct ═ CtTarget gene–CtInternal reference gene。
In a sequencing embodiment, preferably, the methylation level is methylation base number/total base number.
The invention also provides a method for identifying the benign and malignant thyroid nodules, which comprises the following steps:
(1) detecting the level of LIMK1 methylation and the level of SLC17A5 methylation of DNA in a sample using primers described herein,
(2) judging whether the thyroid nodule is benign or malignant according to the methylation level of (1).
In one or more embodiments, the method further comprises DNA extraction and/or quality control prior to step (1).
In one or more embodiments, the sample is from a tissue, cell, or bodily fluid of a mammal, such as thyroid tissue or blood. The mammal is preferably a human. In one or more embodiments, the sample is a thyroid nodule biopsy, preferably a fine needle biopsy. In one or more embodiments, the sample is plasma.
In one or more embodiments, the sample is from a subject having benign or malignant nodules of the thyroid. In one or more embodiments, the sample is from a patient with goiter.
In one or more embodiments, the DNA is whole genome DNA and/or cfDNA.
In one or more embodiments, the DNA is transformed in which unmethylated cytosines are converted to bases that do not bind guanine. The conversion is carried out using an enzymatic method, preferably a deaminase treatment, or the conversion is carried out using a non-enzymatic method, preferably a treatment with bisulfite or bisulfate, more preferably a treatment with calcium bisulfite, sodium bisulfite, potassium bisulfite, ammonium bisulfite, sodium bisulfite, potassium bisulfite and ammonium bisulfite.
In one or more embodiments, the detection includes, but is not limited to: bisulfite conversion based PCR (e.g., methylation specific PCR), DNA sequencing (e.g., bisulfite sequencing, whole genome methylation sequencing, simplified methylation sequencing), methylation sensitive restriction enzyme analysis, fluorometry, methylation sensitive high resolution melting curve, chip-based methylation profile analysis, mass spectrometry (e.g., flight mass spectrometry).
In one or more embodiments, the detection is bisulfite sequencing detection.
In one or more embodiments, the detection is a fluorescent quantitative PCR detection, further comprising the use of a probe as described herein.
In one or more embodiments, the reaction solution for PCR comprises Taq DNA polymerase, PCR buffer (buffer), dNTPs, Mg2+. Preferably, the Taq DNA polymerase is a hot start Taq DNA polymerase. Preferably, Mg2+The final concentration is 1.0-10.0 mM.
In one or more embodiments, the concentration of each primer in the PCR is 200-700 nM.
In one or more embodiments, the concentration of each probe in the PCR is 100-400 nM.
In one or more embodiments, the PCR reaction conditions are, pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 15s, annealing and extension at 60 ℃ for 1min, and 45 cycles.
In one or more embodiments, the interpretation method is: a score is calculated based on the methylation levels of both genes, and a score greater than 0 gives a positive result, i.e., the thyroid nodule is a malignant nodule. In one or more embodiments, a score less than 0 is negative, i.e., the thyroid nodule is a benign nodule.
Preferably, the score is 3.17-0.10 × LIMK1 methylation level-0.31 × SLC17a5 methylation level.
In PCR embodiments, preferably, the methylation level is 2-delta Ct sample to be detected/2- Δ Ct positive standard X 100, where Δ Ct ═ CtTarget gene–CtInternal reference gene。
In a sequencing embodiment, preferably, the methylation level is methylation base number/total base number.
The main advantages of the invention are: by detecting a plurality of target sequences simultaneously, the sensitivity and specificity of identifying benign and malignant thyroid nodules are improved. The PCR method is adopted, the operation is simple, the result is easy to interpret, the requirement on the instrument is not high, and the clinical popularization and application are more convenient in the form of the kit.
Drawings
FIG. 1 is a methylation level analysis of the LIMK1 gene and the SLC17A5 gene of the invention in 37 cases of thyroid cancer and 37 cases of benign nodules of the thyroid.
FIG. 2 is a ROC curve analysis of the combination of the LIMK1 gene and the SLC17A5 gene of the invention for the detection of 22 cases of thyroid cancer and 22 cases of benign nodules of the thyroid.
Detailed Description
The inventors found that the methylation levels of LIMK1 and SLC17a5 genes were associated with malignant thyroid nodules. Referring to thyroid nodules, the terms "benign" and "malignant" as used herein refer to the nature of thyroid nodules. Generally, benign is manifested by slow growth of nodules, uniform texture, good mobility, smooth surface, cystic changes, no enlargement of lymph nodes, no calcification, etc. Malignancy is characterized by uncontrolled malignant cell growth, spread and tissue infiltration. Ultrasound signs that suggest that thyroid nodules are malignant include: the height of the nodule is greater than the width, lack of acoustic halo, micro-calcification, irregular boundaries, reduced echo, solid nodules, abundant blood flow within the nodule, and the like. In some embodiments, the malignant thyroid nodule comprises thyroid cancer.
Herein, methods for detecting DNA Methylation are well known in the art, such as Bisulfite conversion based PCR (e.g., Methylation-specific PCR (MSP)), DNA Sequencing (e.g., Bisulfite Sequencing, BS), Whole genome Methylation Sequencing (WGBS), Reduced Methylation Sequencing (RRBS)), chips, Methylation-Sensitive Restriction enzyme analysis (Methylation-Sensitive Dependent sensitivity Enzymes), fluorescence quantification, Methylation-Sensitive High resolution Melting curve (MS-HRM), chip-based Methylation mapping, mass spectrometry (e.g., mass-spectrometric flight analysis). In one or more embodiments, detecting comprises detecting either strand at the gene or site.
Thus, the present invention relates to a reagent for detecting DNA methylation. Reagents used in the above-described methods for detecting DNA methylation are well known in the art. In addition, in detection methods involving DNA amplification, the reagents for detecting DNA methylation include primers. The primer sequences are methylation specific or non-specific. Preferably, the sequence of the primer comprises a non-methylation specific blocking sequence (Blocker). Blocking sequences may enhance the specificity of methylation detection.
Illustratively, when using fluorescent quantitative PCR, the reagent for detecting DNA methylation may further comprise a probe. The 5 'end of the sequence of the probe is marked with a fluorescent reporter group, and the 3' end is marked with a quenching group. The reaction solution for PCR usually contains Taq DNA polymerase, PCR buffer (buffer), dNTPs, and Mg2+. Preferably, the Taq DNA polymerase is a hot start Taq DNA polymerase. Illustratively, Mg2+The final concentration is 1.0-10.0 mM; the concentration of each primer is 200-700 nM; the concentration of each probe was 100-400 nM; the PCR reaction condition is pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 15s, annealing and extension at 60 ℃ for 1min, and 45 cycles.
The term "variant" or "mutant" as used herein refers to a polynucleotide that has a nucleic acid sequence altered by insertion, deletion or substitution of one or more nucleotides compared to a reference sequence, while retaining its ability to hybridize to other nucleic acids. A mutant according to any of the embodiments herein comprises a nucleotide sequence having at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97% sequence identity to a reference sequence and retaining the biological activity of the reference sequence. Sequence identity between two aligned sequences can be calculated using, for example, BLASTn from NCBI. Mutants also include nucleotide sequences having one or more mutations (insertions, deletions, or substitutions) in the nucleotide sequence of the reference sequence, while still retaining the biological activity of the reference sequence. The plurality of mutations typically refers to within 1-10, such as 1-8, 1-5, or 1-3. The substitution may be a substitution between purine nucleotides and pyrimidine nucleotides, or a substitution between purine nucleotides or between pyrimidine nucleotides. The substitution is preferably a conservative substitution. For example, conservative substitutions with nucleotides of similar or analogous properties are not typically made in the art to alter the stability and function of the polynucleotide. Conservative substitutions are, for example, exchanges between purine nucleotides (A and G), exchanges between pyrimidine nucleotides (T or U and C). Thus, substitution of one or more sites with residues from the same in the polynucleotides of the invention will not substantially affect their activity. Furthermore, the methylation sites (e.g., contiguous CGs) in the variants of the invention are not mutated. That is, the method of the present invention detects methylation of a methylatable site in the corresponding sequence, and a mutation may occur in the base of a non-methylatable site.
The invention also provides a methylation detection kit for identifying benign and malignant thyroid nodules, which comprises a primer molecule and an optional probe molecule, wherein the primer molecule can amplify a fragment of the BIN1 gene obtained by amplifying SEQ ID NO. 1 and 2 or a sequence at least 90% identical to the SEQ ID NO. 1 and 2 as a primer and a fragment of the DNM2 gene obtained by amplifying SEQ ID NO. 3 and 4 or a sequence at least 90% identical to the SEQ ID NO. 3 and 4 as a primer, and the probe molecule comprises sequences shown in SEQ ID NO. 7 and 8 or a sequence at least 90% identical to the sequence. The kit can also comprise a primer for detecting the internal reference gene ACTB and an optional probe molecule for detecting the internal reference gene ACTB, wherein the primer for detecting the internal reference gene ACTB can amplify a segment of the ACTB gene obtained by taking SEQ ID NO. 5 and 6 or a sequence which has at least 90% of homology with the sequence as a primer, and the probe molecule for detecting the internal reference gene ACTB comprises a sequence shown by SEQ ID NO. 9 or a sequence which has at least 90% of homology with the sequence.
The kit can also include a transformed positive standard in which unmethylated cytosines are converted to bases that do not bind guanine. The positive standard may be fully methylated. The kit may further comprise PCR reaction reagents. Preferably, the PCR reaction reagent comprises Taq DNA polymerase, PCR buffer (buffer), dNTPs and Mg2+. The kit can also comprise a DNA detection kitA reagent for the methylation, the reagent being a reagent for use in one or more of the following methods: bisulfite conversion based PCR (e.g., methylation specific PCR), DNA sequencing (e.g., bisulfite sequencing, whole genome methylation sequencing, simplified methylation sequencing), methylation sensitive restriction enzyme analysis, fluorometry, methylation sensitive high resolution melting curve, chip-based methylation profile analysis, mass spectrometry (e.g., flight mass spectrometry). The agent may be selected from one or more of: bisulfite and its derivatives, restriction enzyme sensitive or insensitive to methylation, enzyme digestion buffer, fluorescent dye, fluorescence quencher, fluorescence reporter, exonuclease, alkaline phosphatase, internal standard, and reference substance.
The invention also provides a method for identifying the benign and malignant thyroid nodules, which comprises the following steps: (1) detecting the level of LIMK1 methylation and SLC17a5 methylation of DNA in the sample using the primers described herein, and (2) interpreting thyroid nodule benign and malignant based on the methylation level of (1). Typically, the method further comprises DNA extraction and/or quality control prior to step (1).
As used herein, a "DNA" or "DNA molecule" is a deoxyribonucleic acid. Bases (bp) of DNA are mainly adenine (A), guanine (G), cytosine (C) and thymine (T). The form of DNA includes cDNA, genomic DNA, fragmented DNA, or artificially synthesized DNA. The DNA may be single-stranded or double-stranded.
As used herein, "uracil" or "U" is a component of RNA. An "RNA" or "RNA molecule" is a ribonucleic acid. RNA is a long chain molecule formed by the condensation of ribonucleotides via phosphodiester bonds. RNA has 4 main bases, namely adenine (A), guanine (G), cytosine (C) and uracil (U). In base pairing of RNA, U replaces the position of T in DNA, i.e. a is hydrogen-bonded to U and G is hydrogen-bonded to C.
Transformation can occur between bases of DNA or RNA. "transformation", "cytosine transformation" or "CT transformation" as used herein is the process of converting an unmodified cytosine base (C) to a base that does not bind guanine, such as a uracil base (U), by treating the DNA using non-enzymatic or enzymatic methods. Non-enzymatic or enzymatic methods of performing cytosine conversion are well known in the art. Illustratively, non-enzymatic methods include bisulfite or bisulfate treatments, such as calcium bisulfite, sodium bisulfite, potassium bisulfite, ammonium bisulfite, sodium bisulfate, potassium bisulfate, ammonium bisulfate, and the like. Illustratively, the enzymatic method includes a deaminase treatment. The transformed DNA is optionally purified. DNA purification methods suitable for use herein are well known in the art.
In one or more embodiments, the thyroid nodule benign and malignant interpretation process is: the methylation level of the gene is mathematically analyzed, a score is calculated, and when the score meets a certain threshold, a malignant nodule is identified. Methods of conventional mathematical analysis and processes of determining thresholds are known in the art, an exemplary method being binary Logistic regression analysis. Typically, the threshold is 0. That is, if the score is greater than 0, the result is positive, i.e., the thyroid nodule is a malignant nodule. In one or more embodiments, a score less than 0 is negative, i.e., the thyroid nodule is a benign nodule. Preferably, the score is calculated by the following formula: the score is 3.17-0.10 XLIMK 1 methylation level-0.31 XSLC 17A5 methylation level, wherein the score is more than or equal to 0, and the thyroid nodule is malignant; a score of <0 indicates that the thyroid nodule is benign.
Methods for calculating methylation levels are known in the art. Illustratively, in embodiments where methylation is detected by PCR, the methylation level is 2-delta Ct sample to be detected/2- Δ Ct positive standard X 100, where Δ Ct ═ CtTarget gene–CtInternal reference gene. Alternatively, in embodiments where methylation is detected by sequencing, the level of methylation is the number of methylated bases/total bases.
Herein, the sample is from a mammal, preferably a human. The sample may be from any organ (e.g., thyroid), tissue (e.g., epithelial tissue, connective tissue, muscle tissue, and neural tissue), cell (e.g., thyroid nodule biopsy), or body fluid (e.g., blood, plasma, serum, interstitial fluid, urine). In general, it is sufficient that the sample contains genomic DNA or cfdna (circulating free DNA or Cell free DNA). cfDNA is called circulating free DNA or cell free DNA, and is a degraded DNA fragment that is released into plasma. Illustratively, the sample is a thyroid nodule biopsy, preferably a fine needle biopsy. Alternatively, the sample is plasma, blood or serum.
In a specific embodiment, the method comprises: (1) sample preparation: comprises DNA extraction and quality inspection; (2) DNA transformation: carrying out bisulfite conversion on the DNA obtained in the step (1), and converting unmethylated cytosine (cytosine, C) into uracil (uracil, U); methylated cytosine is not altered after conversion; (3) preparing a reaction mixed solution: comprises PCR reaction solution, primer mixture and probe mixture; (4) preparation of PCR mixture: adding the template DNA transformed by the bisulfite in the step (2) and a positive standard, a negative control or a non-template control (NTC) into the step (3); (5) and (3) PCR reaction: and carrying out PCR reaction and collecting fluorescence. The PCR reaction solution comprises: taq DNA polymerase, PCR buffer (buffer), dNTPs, Mg2+(ii) a The Taq DNA polymerase is hot start Taq DNA polymerase; mg (magnesium)2+The final concentration is 1.0-10.0 mM. The primer mixture is a mixture consisting of the gene primers to be amplified, wherein the final concentration of each primer is 200-700 nM. The probe mixture is a mixture of gene probes to be amplified, wherein the final concentration of each probe is 100-400 nM. The PCR reaction condition is pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 15s, annealing and extension at 60 ℃ for 1min, and 45 cycles.
Examples
The present invention will be described in further detail with reference to the accompanying drawings and specific embodiments. In the following examples, the experimental methods without specifying specific conditions were generally carried out in the same manner as described in the conventional conditions.
Example 1 simplified methylation sequencing screening for genes that differ in the benign and malignant nature of thyroid nodules.
Applicants routinely performed simplified methylation sequencing of the tissues of 37 thyroid cancers and 37 benign nodules of the thyroid and found that the LIMK1 gene and the SLC17a5 gene had differences in methylation levels in the cases of thyroid cancer and benign nodules of the thyroid, with the results shown in figure 1.
Example 2 validation of the relationship between benign and malignant thyroid nodules and Gene methylation
2.1, sample preparation
DNA extraction of 22 cases of thyroid cancer and 22 cases of benign thyroid nodule tissue using QIAamp DNA Mini Kit (QIAGEN, cat # 51304); using qubitsTMThe concentration of the DNA was measured by the dsDNA HS Assay Kit (Thermo, cat # Q32854); quality control was performed using 1% agarose gel electrophoresis.
2.2, DNA transformation
Using MethycodeTMBisulfite Conversion of the DNA obtained in step 1 by the Bisulfit Conversion Kit (Thermo, cat # MECOV50) to convert unmethylated cytosine (cytosine, C) to uracil (uracil, U); methylated cytosines are not altered after conversion.
2.3 PCR mixture preparation
Using the kit provided by the present invention, including PCR reaction solution, primer mixture (SEQ ID NO:1-6), probe mixture (SEQ ID NO:7-9), the preparation of a single sample was performed as shown in Table 1:
TABLE 1 PCR reaction System composition
2.4 fluorescent quantitative PCR
Setting PCR program as 95 deg.c pre-denaturation for 5 min; denaturation at 95 ℃ for 15s, annealing and extension at 60 ℃ for 1min, and 45 cycles. The fluorescence signal was collected during the 60 ℃ annealing extension phase.
2.5, analysis of the test results
Each sample score was calculated using the following formula and the formula in example 1:
methylation level ═ 2-delta Ct sample to be detected/2- Δ Ct positive standard×100。
ΔCt＝CtTarget gene–CtInternal reference gene。
Score 3.17-0.10 × LIMK1 methylation level-0.31 × SLC17a5 methylation level.
The scores for LIMK1 and SLC17A5 genes are shown in Table 2, and the ROC curve analysis is shown in FIG. 2 (AUC of 0.942). According to the interpretation standard provided by the kit, 3 positive thyroid benign nodules are obtained in 22 cases, 20 positive thyroid cancers are obtained in 22 cases, the specificity reaches 86.4%, and the sensitivity is 90.9%.
TABLE 2LIMK1 Gene and SLC17A5 Gene in combination for scoring the benign and malignant discrimination of thyroid nodules
The above-mentioned embodiments only express the embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Sequence listing
<110> secondary first hospital of Zhongshan university
SINGLERA GENOMICS Inc.
<120> thyroid cancer screening marker
<130> 199382
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 1
gttgtgtatc gagtggggta gtg 23
<210> 2
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 2
aaaactaaac caccgaaaat aataac 26
<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 3
gaggttttag tgtgattttt tattgt 26
<210> 4
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 4
aatttaaaat aactcaaccc gaacg 25
<210> 5
<211> 27
<212> DNA
<213> Artificial Sequence
<400> 5
cccttaaaaa ttacaaaaac cacaacc 27
<210> 6
<211> 27
<212> DNA
<213> Artificial Sequence
<400> 6
aggaggttta gtaagttttt tggattg 27
<210> 7
<211> 27
<212> DNA
<213> Artificial Sequence
<400> 7
ttgacgtggc gttttttgtc gtttttg 27
<210> 8
<211> 29
<212> DNA
<213> Artificial Sequence
<400> 8
tcgcgaggtt tttattcgtt gcgtcgttc 29
<210> 9
<211> 30
<212> DNA
<213> Artificial Sequence
<400> 9
accaccaccc aacacacaat aacaaacaca 30
Claims (19)
1. A primer molecule pair for methylation detection of thyroid nodule benign and malignant identification is shown as SEQ ID NO 1 and 2, or SEQ ID NO 3 and 4.
2. A probe molecule for methylation detection of thyroid nodule benign and malignant identification is shown in SEQ ID NO 7 and 8.
3. A methylation detection kit for identifying benign and malignant thyroid nodules, wherein the kit comprises the primer molecule pair of claim 1.
4. The kit of claim 3, further comprising a probe molecule of claim 2.
5. The kit of claim 3, further comprising primers for detecting the reference gene ACTB, wherein the primers for detecting the reference gene ACTB amplify fragments of the ACTB gene amplified by using SEQ ID NO 5 and 6 as primers.
6. The kit of claim 5, further comprising a probe molecule for detecting an internal reference gene ACTB as set forth in SEQ ID NO 9.
7. The kit of any one of claims 3 to 6, wherein the kit further comprises PCR reaction reagents and optionally reagents for detecting DNA methylation.
8. The application of the reagent for detecting the methylation level in the preparation of a kit for identifying benign and malignant thyroid nodules is characterized in that the reagent is used for detecting the methylation level of (1) a fragment of LIMK1 gene obtained by amplification by taking SEQ ID NO:1 and SEQ ID NO: 2 as primers and (2) a fragment of SLC17A5 gene obtained by amplification by taking SEQ ID NO:3 and SEQ ID NO: 4 as primers in a sample, and the identification comprises judging the benign and malignant thyroid nodules according to the methylation level.
9. The use of claim 8, wherein the reagents comprise a pair of primer molecules that amplify a fragment of LIMK1 gene amplified with SEQ ID NOs 1 and 2 as primers or a fragment of SLC17a5 gene amplified with SEQ ID NOs 3 and 4 as primers.
10. The use of claim 9, wherein the primer molecule pair is as defined in claim 1.
11. The use of claim 8, wherein the reagent further comprises a probe molecule capable of hybridizing to: a fragment of LIMK1 gene amplified by using SEQ ID NO. 1 and SEQ ID NO. 2 as primers or a fragment of SLC17A5 gene amplified by using SEQ ID NO. 3 and SEQ ID NO. 4 as primers.
12. The use according to claim 11, wherein the probe molecule is according to claim 4.
13. The use of any one of claims 8 to 12, wherein the sample is from a tissue, cell or body fluid of a mammal.
14. The use of any one of claims 8 to 12, wherein the sample is from mammalian thyroid tissue or blood.
15. The use of any one of claims 8 to 12, wherein the sample is derived from mammalian plasma.
16. The use of any one of claims 8 to 12, wherein the DNA is whole genome DNA and/or cfDNA.
17. The use of any one of claims 8-12, wherein the detecting comprises: PCR based on bisulfite conversion, DNA sequencing, methylation sensitive restriction enzyme analysis, fluorescence quantification, methylation sensitive high resolution melting curve method, chip-based methylation map analysis, and mass spectrum.
18. The use of claim 17, wherein the assay is a fluorescent quantitative PCR assay.
19. The use according to any one of claims 8 to 12, wherein the interpretation method is: a score was calculated based on the methylation levels of both genes, and thyroid nodules with a score greater than 0 were malignant nodules, with a score of = 3.17-0.10 × LIMK1 methylation level-0.31 × SLC17a5 methylation level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010037595.3A CN111197087B (en) | 2020-01-14 | 2020-01-14 | Thyroid cancer differential marker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010037595.3A CN111197087B (en) | 2020-01-14 | 2020-01-14 | Thyroid cancer differential marker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111197087A CN111197087A (en) | 2020-05-26 |
| CN111197087B true CN111197087B (en) | 2020-11-10 |
Family
ID=70744838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010037595.3A Active CN111197087B (en) | 2020-01-14 | 2020-01-14 | Thyroid cancer differential marker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111197087B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114277115A (en) * | 2020-09-27 | 2022-04-05 | 上海鹍远生物科技股份有限公司 | Thyroid nodule benign and malignant related marker and application thereof |
| CN116287222A (en) * | 2021-12-09 | 2023-06-23 | 江苏鹍远生物科技股份有限公司 | Methylation marker for diagnosis of benign and malignant thyroid cancer nodules and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011620A2 (en) * | 2006-07-21 | 2008-01-24 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| WO2008122447A2 (en) * | 2007-04-10 | 2008-10-16 | Epigenomics Ag | Dna methylation assay for the diagnosis or prognosis of medical conditions |
| WO2011128820A2 (en) * | 2010-04-16 | 2011-10-20 | Koninklijke Philips Electronics N.V. | Methods for the analysis of breast cancer disorders |
| CN105039523A (en) * | 2008-11-17 | 2015-11-11 | 威拉赛特公司 | Methods and compositions of molecular profiling for disease diagnostics |
| CN108138242A (en) * | 2015-07-16 | 2018-06-08 | 迪莫·迪特里希 | Determine the method being mutated in genomic DNA, the purposes of this method and the kit for implementing this method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103866039B (en) * | 2014-04-04 | 2015-05-27 | 厦门大学 | Specific site methylation level detection primer of human thyroid cancer tissue gene and application of detection primer |
-
2020
- 2020-01-14 CN CN202010037595.3A patent/CN111197087B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011620A2 (en) * | 2006-07-21 | 2008-01-24 | Epigenomics Ag | Methods and nucleic acids for analyses of cellular proliferative disorders |
| WO2008122447A2 (en) * | 2007-04-10 | 2008-10-16 | Epigenomics Ag | Dna methylation assay for the diagnosis or prognosis of medical conditions |
| CN105039523A (en) * | 2008-11-17 | 2015-11-11 | 威拉赛特公司 | Methods and compositions of molecular profiling for disease diagnostics |
| WO2011128820A2 (en) * | 2010-04-16 | 2011-10-20 | Koninklijke Philips Electronics N.V. | Methods for the analysis of breast cancer disorders |
| CN108138242A (en) * | 2015-07-16 | 2018-06-08 | 迪莫·迪特里希 | Determine the method being mutated in genomic DNA, the purposes of this method and the kit for implementing this method |
Non-Patent Citations (2)
| Title |
|---|
| Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues;Dimo Dietrich等;《J Histochem Cytochem.》;20090119;第57卷(第5期);第477页摘要，第479页右栏第2段-第480页右栏第1段，第480页表1 * |
| Methylation Markers Differentiate Thyroid Cancer From Benign Nodules;J K Stephen等;《J Endocrinol Invest.》;20170613;第41卷(第2期);1-6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111197087A (en) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100058449A (en) | Specific amplification of tumor specific dna sequences | |
| WO2023071890A1 (en) | Methylation biomarker related to lymph node metastasis of gastric cancer, and combination and detection kit thereof | |
| CN110129436A (en) | The Serial No. of DNA methylation is analyzed | |
| CN111197087B (en) | Thyroid cancer differential marker | |
| CN111100866B (en) | Gene segment for identifying benign and malignant thyroid nodules and application thereof | |
| CN113186278B (en) | Thyroid nodule benign and malignant related marker and application thereof | |
| TW202144586A (en) | Methods and kits for screening colorectal neoplasm | |
| CN113493835A (en) | Method and kit for screening large intestine tumor by detecting methylation state of BCAN gene region | |
| WO2021143709A1 (en) | Reagent for detecting dna methylation and use thereof | |
| WO2018211404A1 (en) | Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer | |
| US9765397B2 (en) | Method of detecting methylation | |
| WO2023104136A1 (en) | Methylation marker in diagnosis of benign and malignant nodules of thyroid cancer and applications thereof | |
| JP2003259874A (en) | Testing method | |
| WO2023274350A1 (en) | Benign and malignant thyroid nodule related marker and use thereof | |
| CN115094139B (en) | Application of reagent for detecting methylation level in preparation of bladder cancer diagnosis product and bladder cancer diagnosis kit | |
| CN114277115A (en) | Thyroid nodule benign and malignant related marker and application thereof | |
| CN115851959B (en) | Reagent for diagnosis or auxiliary diagnosis of esophageal squamous cell carcinoma and precancerous lesions and detection kit | |
| CN115161400B (en) | DNA methylation detection method and reagent used in same | |
| CN117721207A (en) | Composition for detecting cervical cancer and/or cervical high-grade lesions and application thereof | |
| JP4682275B2 (en) | Method for determining prognosis of mammalian neuroblastoma | |
| CN113493834A (en) | Method and kit for screening large intestine tumor by detecting methylation state of PKNOX2 gene region | |
| CN115838799A (en) | Application of reagent for detecting gene methylation in preparation of product for diagnosing colorectal cancer | |
| CN117721203A (en) | Composition for detecting thyroid cancer and application thereof | |
| CN116121371A (en) | Application of reagent for detecting methylation level of target region in TLX1 gene in preparation of esophageal cancer diagnosis product | |
| CN116904598A (en) | Nucleic acid combination, reagent and kit for detecting primary liver cancer and application of nucleic acid combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510062 No. 58, Zhongshan Second Road, Guangzhou, Guangdong Patentee after: THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN University Patentee after: Shanghai Fuyuan Biotechnology Co.,Ltd. Address before: 510062 No. 58, Zhongshan Second Road, Guangzhou, Guangdong Patentee before: THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN University Patentee before: SINGLERA GENOMICS (SHANGHAI) Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510062 No. 58, Zhongshan Second Road, Guangzhou, Guangdong Patentee after: THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN University Patentee after: Jiangsu Huayuan Biotechnology Co.,Ltd. Address before: 510062 No. 58, Zhongshan Second Road, Guangzhou, Guangdong Patentee before: THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN University Patentee before: Shanghai Fuyuan Biotechnology Co.,Ltd. |